0001209191-23-001995.txt : 20230105 0001209191-23-001995.hdr.sgml : 20230105 20230105173902 ACCESSION NUMBER: 0001209191-23-001995 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230103 FILED AS OF DATE: 20230105 DATE AS OF CHANGE: 20230105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Doerfler Douglas CENTRAL INDEX KEY: 0001874482 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40674 FILM NUMBER: 23512632 MAIL ADDRESS: STREET 1: C/O MAXCYTE, INC. STREET 2: 22 FIRSTFIELD ROAD, SUITE 110 CITY: GAITHERSBURG STATE: MD ZIP: 20878 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MAXCYTE, INC. CENTRAL INDEX KEY: 0001287098 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 522210438 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 22 FIRSTFIELD ROAD STREET 2: SUITE 250 CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 301-517-5556 MAIL ADDRESS: STREET 1: 22 FIRSTFIELD ROAD STREET 2: SUITE 250 CITY: GAITHERSBURG STATE: MD ZIP: 20878 FORMER COMPANY: FORMER CONFORMED NAME: MAXCYTE INC DATE OF NAME CHANGE: 20040415 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-01-03 0 0001287098 MAXCYTE, INC. MXCT 0001874482 Doerfler Douglas C/O MAXCYTE, INC. 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850 1 1 0 0 President and CEO Common Stock 2023-01-03 4 M 0 10613 0.04 A 343810 D Common Stock 2023-01-03 4 S 0 10613 5.13 D 333197 D Common Stock 2023-01-04 4 M 0 9153 0.04 A 342350 D Common Stock 2023-01-04 4 S 0 9153 5.07 D 333197 D Common Stock 2023-01-05 4 M 0 10234 0.04 A 343431 D Common Stock 2023-01-05 4 S 0 10234 5.04 D 333197 D Employee Stock Option (right to buy) 0.04 2023-01-03 4 M 0 10613 0.00 D 2024-11-11 Common Stock 10613 434467 D Employee Stock Option (right to buy) 0.04 2023-01-04 4 M 0 9153 0.00 D 2024-11-11 Common Stock 9153 425314 D Employee Stock Option (right to buy) 0.04 2023-01-05 4 M 0 10234 0.00 D 2024-11-11 Common Stock 10234 415080 D The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024. The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.49, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.19, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. This option is fully vested and exercisable. /s/ Brian F. Leaf, attorney-in-fact 2023-01-05